Levitee Labs - CEO, Pouya Farmand.
CEO, Pouya Farmand.
Source: Levitee Labs.
  • Levitee Labs (LVT) increased revenue by 10 per cent in one month
  • Levitee has recorded an unaudited revenue of $893,863 for the month of August
  • Earth Circle Organics, Levitee’s direct-to-consumer and wholesaler of supplements and superfood products, increased its sales by 14.5 per cent
  • Levitee Labs is a leader in the integrative wellness space
  • Levitee (LVT) is up 1.06 per cent today, and is trading at C$0.48 per stock as of 10:50 a.m. ET

Levitee Labs (LVT) increased revenue by 10 per cent in one month.

Since acquiring ACT Medical Centres in July, Levitee Pharmacies sees its revenue increase by 10 per cent.

 On a consolidated basis, Levitee Labs records an unaudited revenue of $893,863 for the month of August.

Earth Circle Organics, Levitee’s direct-to-consumer and wholesaler of supplements and superfood products increased its sales by 14.5 per cent. This was made possible through further scaling of their direct-to-consumer business and introducing a multidisciplinary component to Levitee Labs’ healthcare assets and incorporating new mental health and treatment patterns.

Pouya Farmand, founder and CEO of the company, states it is successfully executing strategic plans to change internally and increase growth through cross-sales opportunities.

Levitee will look to build more on its fast-growing expansion plans for the next 12 months. The core focus for Levitee is to generate revenue by taking advantage of profitable business investments, increasing margins, further developing its portfolio of assets through organic growth and other major growth opportunities that become available in the market.

Levitee Labs is a leader in the integrative wellness space. It aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies into a medical home care model.

Levitee (LVT) is up 1.06 per cent today, and is trading at C$0.48 per share as of 10:50 a.m. ET.

More From The Market Online

Sona Nanotech reveals results from breast cancer study

Sona Nanotech (CSE:SONA) reveals additional results from the triple-negative breast cancer murine model portion of its research study.

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.